{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:02:39Z","timestamp":1791252159957,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunobiology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.imbio.2012.07.014","type":"journal-article","created":{"date-parts":[[2012,9,8]],"date-time":"2012-09-08T00:27:54Z","timestamp":1347064074000},"page":"1080-1087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders"],"prefix":"10.1016","volume":"217","author":[{"given":"Antonio M.","family":"Risitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.imbio.2012.07.014_bib0005","first-page":"241","article-title":"Successful treatment of complement mediated refractory hemolysis associated with cold and warm autoantibodies using eculizumab","volume":"94","author":"Bommer","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.imbio.2012.07.014_bib0010","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"114","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0015","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1182\/blood-2009-03-195966","article-title":"How I treat paroxysmal nocturnal hemoglobinuria","volume":"113","author":"Brodsky","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0020","unstructured":"ClinicalTrials.gov. 2011. A service of the U.S. National Institutes of Health. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01335165."},{"key":"10.1016\/j.imbio.2012.07.014_bib0025","unstructured":"ClinicalTrials.gov. 2011.A service of the U.S. National Institutes of Health. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01303952."},{"issue":"110","key":"10.1016\/j.imbio.2012.07.014_bib0030","first-page":"1290","article-title":"Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes","volume":"15","author":"Ferreira","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0035","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood-2011-06-359646","article-title":"Design and development of TT30, a novel C3d-targeted C3\/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases","volume":"118","author":"Fridkis-Hareli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0040","doi-asserted-by":"crossref","first-page":"193a","DOI":"10.1182\/blood.V118.21.193.193","article-title":"Eculizumab is an effective long-term treatment in patients with atypical hemolytic uremic syndrome (aHUS) resistant to plasma exchange\/infusion (PE\/PI): results of an extension study","volume":"118","author":"Greenbaum","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0045","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1172\/JCI101081","article-title":"Studies on the destruction of red blood cells II. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: certain immunological aspects of the hemolytic mechanism with special reference to serum complement","volume":"18","author":"Ham","year":"1939","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imbio.2012.07.014_bib0050","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3324\/haematol.2009.016121","article-title":"French Society of Hematology. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"95","author":"Helley","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.imbio.2012.07.014_bib0055","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3324\/haematol.2009.007229","article-title":"Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization","volume":"95","author":"Hill","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.imbio.2012.07.014_bib0060","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imbio.2012.07.014_bib0065","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imbio.2012.07.014_bib0070","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0075","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1600-065X.2008.00641.x","article-title":"The spectrum of complement alternative pathway-mediated diseases","volume":"223","author":"Holers","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.imbio.2012.07.014_bib0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI114172","article-title":"Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria","volume":"84","author":"Holguin","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imbio.2012.07.014_bib0085","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1172\/JCI114311","article-title":"Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria","volume":"84","author":"Holguin","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imbio.2012.07.014_bib0090","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4049\/jimmunol.148.2.498","article-title":"Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor","volume":"148","author":"Holguin","year":"1992","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2012.07.014_bib0095","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1172\/JCI108547","article-title":"The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man","volume":"58","author":"Jaffe","year":"1976","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imbio.2012.07.014_bib0100","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1172\/JCI36088","article-title":"C3b deposition on human erythrocytes induces the formation of a membrane skeleton-linked protein complex","volume":"119","author":"Karnchanaphanurach","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imbio.2012.07.014_bib0105","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.med.59.060106.185110","article-title":"Complement regulatory genes and haemolytic uremic syndromes","volume":"59","author":"Kavanagh","year":"2008","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.imbio.2012.07.014_bib0110","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s00467-010-1555-5","article-title":"Genetics and complement in atypical HUS","volume":"25","author":"Kavanagh","year":"2010","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.imbio.2012.07.014_bib0115","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0120","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood.V33.4.607.607","article-title":"Erythrocyte acetylcholinesterase deficiency in paroxysmal nocturnal hemoglobinuria (PNH). A comparison of the complement-sensitive and insensitive populations","volume":"33","author":"Kunstling","year":"1969","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0125","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Complement blockade in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imbio.2012.07.014_bib0130","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nbt0811-671","article-title":"E. coli crisis opens door for Alexion drug trial","volume":"29","author":"Laursen","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.imbio.2012.07.014_bib0135","doi-asserted-by":"crossref","first-page":"3303a","DOI":"10.1182\/blood.V118.21.3303.3303","article-title":"Eculizumab is an effective long-term treatment in patients with atypical hemolytic uremic syndrome (aHUS) previously receiving chronic plasma exchange\/infusion (PE\/PI): extension study results","volume":"118","author":"Licht","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0140","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/blood-2009-09-244285","article-title":"A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement","volume":"115","author":"Lindorfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0145","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.imbio.2012.07.014_bib0150","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3324\/haematol.2009.017848","article-title":"Paroxysmal nocturnal hemoglobinuria and eculizumab","volume":"95","author":"Luzzatto","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.imbio.2012.07.014_bib0155","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1182\/blood.V79.6.1400.1400","article-title":"Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes","volume":"79","author":"Mahoney","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0160","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nm0895-839","article-title":"Complement-specific antibodies: designing novel anti-inflammatories","volume":"1","author":"Matis","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.imbio.2012.07.014_bib0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1172\/JCI113043","article-title":"Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes","volume":"80","author":"Medof","year":"1987","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imbio.2012.07.014_bib0170","first-page":"1","article-title":"Human protectin (CD59), an 18,000\u201320,000MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers","volume":"71","author":"Meri","year":"1990","journal-title":"Immunology"},{"key":"10.1016\/j.imbio.2012.07.014_bib0175","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2141.1989.tb00260.x","article-title":"Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor)","volume":"73","author":"Merry","year":"1989","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.imbio.2012.07.014_bib0180","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.7680492","article-title":"The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis","volume":"259","author":"Miyata","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.imbio.2012.07.014_bib0185","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/eji.1830221029","article-title":"Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene","volume":"22","author":"Motoyama","year":"1992","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.imbio.2012.07.014_bib0195","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.bi.57.070188.001541","article-title":"Molecular organization and function of the complement system","volume":"57","author":"M\u00fcller-Eberhard","year":"1988","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.imbio.2012.07.014_bib0200","doi-asserted-by":"crossref","first-page":"4772a","DOI":"10.1182\/blood.V118.21.4772.4772","article-title":"Eculizumab (ECU) significantly improves health-related quality of life (hrqol) in patients with atypical hemolytic uremic syndrome (aHUS)","volume":"118","author":"Muus","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0205","series-title":"Wintrobe's Clinical Hematology","first-page":"1157","article-title":"Autoimmune hemolytic anemias","author":"Neff","year":"2003"},{"key":"10.1016\/j.imbio.2012.07.014_bib0210","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4049\/jimmunol.129.1.184","article-title":"Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system","volume":"129","author":"Nicholson-Weller","year":"1982","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2012.07.014_bib0215","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1073\/pnas.80.16.5066","article-title":"Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor","volume":"80","author":"Nicholson-Weller","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.imbio.2012.07.014_bib0220","first-page":"7","article-title":"Decay accelerating factor (CD55)","volume":"178","author":"Nicholson-Weller","year":"1992","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.imbio.2012.07.014_bib0225","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imbio.2012.07.014_bib0230","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","article-title":"Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome","volume":"182","author":"Orth","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2012.07.014_bib0235","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/emmm.201100169","article-title":"Inhibition of terminal complement activation in severe Shiga toxin-associated HUS \u2013 perfect example for a fast track from bench to bedside","volume":"3","author":"Orth-H\u00f6ller","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.imbio.2012.07.014_bib0240","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1084\/jem.154.3.856","article-title":"Formation of the initial C3 convertase of the alternative complement pathway: acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3","volume":"154","author":"Pangburn","year":"1981","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imbio.2012.07.014_bib0245","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1084\/jem.157.6.1971","article-title":"Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes","volume":"157","author":"Pangburn","year":"1983","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imbio.2012.07.014_bib0250","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1749-6632.1983.tb18116.x","article-title":"Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3","volume":"421","author":"Pangburn","year":"1983","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.imbio.2012.07.014_bib0255","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1073\/pnas.80.17.5430","article-title":"Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria","volume":"80","author":"Pangburn","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.imbio.2012.07.014_bib0260","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.4049\/jimmunol.131.4.1930","article-title":"C3b deposition during activation of the alternative complement pathway and the effect of deposition on the activating surface","volume":"131","author":"Pangburn","year":"1983","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2012.07.014_bib0265","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1172\/JCI110457","article-title":"Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria","volume":"69","author":"Parker","year":"1982","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imbio.2012.07.014_bib0270","series-title":"Wintrobe's Clinical Hematology","first-page":"1139","article-title":"Mechanisms of immune destruction of erythrocytes","author":"Parker","year":"2003"},{"key":"10.1016\/j.imbio.2012.07.014_bib0275","first-page":"273","article-title":"Complement inhibitor on its way to clinical application","volume":"632","author":"Ricklin","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.imbio.2012.07.014_bib0280","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2008-04-151613","article-title":"Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab","volume":"112","author":"Risitano","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0285","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0290","doi-asserted-by":"crossref","first-page":"158a","DOI":"10.1182\/blood.V114.22.158.158","article-title":"TT30, a novel regulator of the complement alternative pathway (cap), inhibits hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) erythrocytes and prevents upstream c3 binding on their surface in an in vitro model","volume":"114","author":"Risitano","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0295","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1056\/NEJMc1010351","article-title":"Paroxysmal nocturnal hemoglobinuria: hemolysis before and after eculizumab","volume":"363","author":"Risitano","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imbio.2012.07.014_bib0300","series-title":"Anemia","first-page":"331","article-title":"Paroxysmal nocturnal hemoglobinuria","author":"Risitano","year":"2012"},{"key":"10.1016\/j.imbio.2012.07.014_bib0305","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1182\/blood-2011-12-398792","article-title":"The complement receptor 2\/factor H fusion protein TT30 protects paroxysmal nocturnalhemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization","volume":"119","author":"Risitano","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0310","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1172\/JCI105388","article-title":"Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody","volume":"45","author":"Rosse","year":"1966","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imbio.2012.07.014_bib0315","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood.V37.5.556.556","article-title":"The life-span of complement-sensitive and \u2013insensitive red cells in paroxysmal nocturnal hemoglobinuria","volume":"37","author":"Rosse","year":"1971","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0320","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1182\/blood-2009-01-196329","article-title":"Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease","volume":"113","author":"Roth","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0325","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1600-0609.2009.01320.x","article-title":"Cold agglutinin disease","volume":"84","author":"Roth","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.imbio.2012.07.014_bib0330","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.imbio.2012.07.014_bib0335","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/333565a0","article-title":"The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria","volume":"333","author":"Selvaraj","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.imbio.2012.07.014_bib0340","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.4049\/jimmunol.136.5.1777","article-title":"Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9","volume":"136","author":"Shin","year":"1986","journal-title":"J. Immunol."},{"issue":"s2","key":"10.1016\/j.imbio.2012.07.014_bib0345","first-page":"196a","article-title":"In vitro complement protein 5 (C5) blockade recapitulates the complement protein 3 (C3) binding to GPI-negative erythrocytes observed in paroxysmal nocturnal hemoglobinuria (PNH) patients on eclizumab","volume":"95","author":"Sica","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.imbio.2012.07.014_bib0355","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1084\/jem.177.2.517","article-title":"Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria","volume":"177","author":"Takahashi","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imbio.2012.07.014_bib0360","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0092-8674(93)90250-T","article-title":"Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria","volume":"73","author":"Takeda","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.imbio.2012.07.014_bib0365","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1084\/jem.144.5.1147","article-title":"Modulation of the alternative complement pathway by \u03b21H globulin","volume":"144","author":"Whaley","year":"1976","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imbio.2012.07.014_bib0375","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood.V78.3.820.820","article-title":"Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum","volume":"78","author":"Wilcox","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2012.07.014_bib0380","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJM199010253231707","article-title":"Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria","volume":"323","author":"Yamashina","year":"1990","journal-title":"N. Engl. J. Med."}],"container-title":["Immunobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298512001787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298512001787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:35:05Z","timestamp":1759250105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0171298512001787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":73,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0171298512001787"],"URL":"https:\/\/doi.org\/10.1016\/j.imbio.2012.07.014","relation":{},"ISSN":["0171-2985"],"issn-type":[{"value":"0171-2985","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders","name":"articletitle","label":"Article Title"},{"value":"Immunobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imbio.2012.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}]}}